Gut microbiota signatures associated with KRAS mutations in patients with colorectal cancer (CRC) have been identified by researchers. Their findings suggest that the gut microbes may serve as ...

Verastem (NASDAQ:VSTM) executives said the company’s transition to a commercial-stage business accelerated in 2025 following ...

Avutometinib and defactinib combination shows over one-year median PFS in recurrent LGSOC patients, with notable efficacy in KRAS-mutant and KRAS-wild-type populations. Verastem Oncology plans FDA ...

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapy The majority of ...

Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer.

Validation of the survival benefit from metformin use in patients with type 2 diabetes and colorectal cancer. This is an ASCO Meeting Abstract from the 2013 Gastrointestinal Cancers Symposium. This ...